Inventor · disambiguated record
Nils Ove Gustafsson
Also filed as: GUSTAFSSON NILS OVE
21 granted patents·5 pending applications·231 citations·filing 1996–2024
94Inventor score
Top patents by PatentIndex Score
26 records- 0197US10975046B2Crystal modifications of odevixibatALBIREO AB·Filed 2019·Granted Apr 13, 2021·22 cites·20 claims
- 0296US11801226B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2020·Granted Oct 31, 2023·11 cites·15 claims
- 0396US11365182B2Crystal modifications of odevixibatALBIREO AB·Filed 2020·Granted Jun 21, 2022·10 cites·18 claims
- 0496US10786529B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Sep 29, 2020·12 cites·25 claims
- 0595US12091394B2Crystal modifications of odevixibatALBIREO AB·Filed 2022·Granted Sep 17, 2024·4 cites·27 claims
- 0695US11802115B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2019·Granted Oct 31, 2023·11 cites·16 claims
- 0793US10441605B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·22 claims
- 0893US10441604B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·18 claims
- 0991US11007142B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted May 18, 2021·5 cites·21 claims
- 1091US10610543B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2018·Granted Apr 7, 2020·4 cites·19 claims
- 1190US6120787ASustained release particlesBIOGRAM AB·Filed 1996·Granted Sep 19, 2000·132 cites·32 claims
- 1288US10864228B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Dec 15, 2020·2 cites·30 claims
- 1388US10799527B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Oct 13, 2020·2 cites·30 claims
- 1486US10881685B2Cholestyramine granules, oral cholestyramine formulations and use thereofALBIREO AB·Filed 2018·Granted Jan 5, 2021·2 cites·27 claims
- 1585US2025019354A1Crystal Modifications of OdevixibatALBIREO AB·Filed 2024·Application pending·0 cites
- 1682US12508234B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2023·Granted Dec 30, 2025·0 cites·20 claims
- 1780US10722457B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Jul 28, 2020·1 cites·21 claims
- 1877US2024130976A1Pharmaceutical Formulation of OdevixibatALBIREO AB·Filed 2023·Application pending·0 cites
- 1973US8017152B2Cores and microcapsules suitable for parenteral administration as well as process for their manufactureSTRATOSPHERE PHARMA AB·Filed 2006·Granted Sep 13, 2011·1 cites·20 claims
- 2069US10758563B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Sep 1, 2020·0 cites·27 claims
- 2169US10493096B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Dec 3, 2019·0 cites·22 claims
- 2267US12023311B2Delayed release pharmaceutical formulations comprising valproic acid, and uses thereofCERENO SCIENT AB·Filed 2022·Granted Jul 2, 2024·0 cites·22 claims
- 2353US2020046757A1Cholestyramine pellets, oral cholestyramine formulations, and uses thereofALBIREO AB·Filed 2019·Application pending·0 cites
- 2453US2020046758A1Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2019·Application pending·0 cites
- 2552US11395808B2Delayed release pharmaceutical formulations comprising valproic acid, and uses thereofCERENO SCIENT AB·Filed 2017·Granted Jul 26, 2022·0 cites·18 claims
- 2650US2019046451A1Cholestyramine pellets, oral cholestyramine formulations and use thereofALBIREO AB·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →